Teladoc (TDOC) Q2 Revenue Tops Consensus, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Teladoc (TDOC) Falls 6% on Growing Losses and Weak Guidance to Prompt a Downgrade to 'Hold' at Deutsche Bank
July 28, 2021 10:01 AM EDTShares of Teladoc Health (NYSE: TDOC) are down more than 6% in todays trading session after the company presented disappointing Q2 results.
The company reported a loss of $0.86 per share while the surveyed analysts were expecting a loss of just $0.53 per share. Losses have more than doubled compared to $0.34 a year ago. Revenue grew 109% year-over-year to $503 million.
Teladoc Health delivered a strong second quarter, marked by exciting new client wins, product launches, and tremendous progress on our quest to be the category-defining provider of whole person virtual care, said Jason Gorevic, chief executive... More
Teladoc (TDOC) PT Lowered to $205 at Needham & Company
July 28, 2021 8:54 AM EDTNeedham & Company analyst Ryan MacDonald lowered the price target on Teladoc (NYSE: TDOC) to $205.00 (from $235.00) while maintaining a Buy rating.
The analyst commented, "We are reiterating our Buy rating, while lowering our PT to $205 following the company's solid 2Q in which organic growth remained... More
Teladoc (TDOC) PT Lowered to $185 at Cantor Fitzgerald
July 28, 2021 6:46 AM EDTCantor Fitzgerald analyst Steven Halper lowered the price target on Teladoc (NYSE: TDOC) to $185.00 (from $210.00) while maintaining a Neutral rating.
The analyst commented, "We reiterate our Neutral rating on TDOC shares and lower our price target to $185 from $210. After the market close on Tuesday, July 27, TDOC reported 2Q21 results. Revenue and... More
